The Amarin Win and the Next Big Question: What Will the FDA Do? [Drug and Device Law]

John Sullivan, a member of Cozen O’Connor’s Commercial Litigation Department, discusses Amarin’s successful motion for a preliminary injunction in its First Amendment challenge to the FDA’s regulation of off-label marketing and discusses what this means for the FDA.

To read the article, click here.

Share Page On LinkedIn

Related Attorneys

John J. Sullivan


(212) 453-3729

Related Practices